Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium (90Y) citrate colloid
- Development stage
- Unknown
- Lead developer
- CISBIO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Administration
- Intraarticular
01
Overview
Yttrium (90Y) citrate colloid (YMM-1) is a therapeutic radiopharmaceutical developed by CIS bio international (now part of Curium) for radiosynoviorthesis (RSO) of the knee joint. It is administered via intra-articular injection to treat severe joint pain and inflammation associated with chronic inflammatory joint diseases, particularly rheumatoid arthritis, monoarthritis, or oligoarthritis, as well as hemophilic arthropathy. Upon injection, the colloidal particles of yttrium-90 citrate are phagocytosed by the superficial lining cells of the inflamed synovial membrane. The beta radiation emitted by the yttrium-90 isotope (with a physical half-life of approximately 64 hours) delivers localized radiation to the synovium, leading to cell death, fibrosis, and sclerosis of the synovial membrane, thereby reducing joint effusion and pain.
- Other names
- colloidal yttrium-90 citrateyttrium (90Y) citrateyttrium (90Y) citrate colloidyttrium-90 citrateyttrium90 citrateyttrium 90 citrateyttrium-90 citrate colloidyttrium90 citrate colloidyttrium 90 citrate colloid
02
Targets
DNA
Beyond the preview
Go deeper on yttrium (90Y) citrate colloid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium (90Y) citrate colloid.